Argenx highlights 2024 strategic priorities

Reported $1.2 billion in preliminary* full-year 2023 global net product sales submitted sbla to fda for vyvgart ® hytrulo for cidp with priority review voucher (prv); if approved, launch expected mid-2024 reported positive data from phase 2 arda study establishing proof-of-concept for empasiprubart in mmn data from six phase 2 proof-of-concept trials expected by end of 2024 nominated four new pipeline candidates with ind filings expected by end of 2025 january 8, 2024, 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported preliminary financial results for the full-year 2023, including global net product sales (inclusive of both vyvgart® and vyvgart hytrulo), and announced its strategic priorities for 2024. “in 2023, we reached more than 6,000 patients globally, making vyvgart available to gmg patients around the world,” said tim van hauwermeiren, chief executive officer of argenx.
ARGX Ratings Summary
ARGX Quant Ranking